Total Utang marang Modal Citius Oncology, Inc (CTOR)

Citius Oncology, Inc. (CTOR) is valued by the medical community as a promising expert in the specialized niche of oncology. The business relies on the launch of the drug LYMPHIR and the development of new agents against rare tumors. This price chart reflects a debt-to-equity ratio of 0.23, which is critical given the strict FDA oversight and the patent protection of toxins.

This ratio compares the total liabilities of Citius Oncology, Inc. (CTOR) to its total equity. The metric determines the share of debt financing within the asset structure, assessing financial stability and default risks. The company may require additional leverage to expand the LYMPHIR drug into US hospital networks. By analyzing this debt-to-equity chart, an investor can determine the balance between external debt and internal resources.